Welcome and Introductions – Jessie Dresner

OPAC Moving Forward – Jessie Dresner
- Josh Moore, the new pharmacy director, will be taking responsibility for OPAC
- Attendees asked to consider the scope, goals and structure of the meeting and provide feedback
- Dana Bernier, Constituent Education, will be heading the education subcommittee. To strengthen education efforts, YouTube videos have been created and put on our website. Jessie would like feedback regarding the effectiveness of the videos.

CMT-Relias Contract – Jessie Dresner
- CMT would like to pilot a portal to offer peer to peer comparison related to prescribing habits. Attendees asked to provide feedback regarding whether they are interested in a demonstration of the portal

MHD Presentation – Elizabeth Sissom, Angela Wilson, Dr. Mark Roaseau
- Update on grandfathering in regard to moving from non-preferred to preferred drugs. Concern was expressed regarding it being an inconvenience for patients and physicians and that Medicaid should not pay for the expensive drugs initially so the change would not be required. Dr. Roaseau explained there is a process to determine what drugs are...
covered, including seeking insight from three advisory committees. Also explained due to rebates, most expensive commercial drug may not be the most expensive to the state. Members asked about a way to tell what has changed and what is preferred. Advised there is a Conduent database available as well as a quarterly report. Links will be provided to group following meeting.

• Update on August 8, 2019 Benzodiazepine edit. This will be done in two phases, first phase is to keep new users from becoming chronic users. The second will include tapering for chronic users. Concerns were expressed about patients who experience spasticity and use benzos PRN for breakthroughs. Advised to contact MHD for those unique situations for prior approval. Physicians also asked what guidelines MHD will use to determine recommended dosages. Dr. Roaseau advised it is based upon the FDA maximum allowable dosage. MHD does not currently post the FDS maximum allowable dosages. November 2018 opiate edit (Chelsea Pendleton, WIPRO). If the correct diagnosis code is in the billing history, the request will go through transparently with no need for a manual prior authorization process. There are ongoing issues with the way requests are being submitted.
  o Diagnosis must be billed or otherwise provided during the 90 days prescription period approved.
  o An approvable diagnosis must be in first five diagnoses to be captured by our system; often there are many diagnoses and pain is low on the list – attendees indicated pain is often not discussed in early conversations, leading it to be lower on the list
  o Documentation is lacking or indicates a different diagnosis with no supporting progress notes
  o Multiple faxes are received for the same person, but with differing information
  o Attestation forms are being submitted with no documentation, these forms are to be sent only when provided by WIPRO following receipt of needed documentation
  o When patients are on two opioids, the request does not include both

• It was requested that clarification regarding the alternative therapies be distributed due to misunderstanding regarding age eligibility. New coverage is for those 21 years and older as children were covered previously.

SUPPORT Act and other initiatives – Jessie Dresner, Terri Woodward

• Working to combine multiple initiatives related to better outcomes for mothers/children, including access, quality and social determinants. Seeking input from other agencies, coalitions, etc. to develop a document to consolidate.

• SUD waiver is out for public comment until 08/14/2019

Pharmacy related initiatives – Jessie Dresner, Angela Wilson, Dr. Mark Roaseau

• Suggestions from the recent transformation report will be considered, but not all will be addressed at this time. The report is available at https://dss.mo.gov/mhd/mt/index.htm

Response to CDC guidelines – Dr. Mark Roaseau
• Missouri has taken a realistic approach to implementation of the guidelines and is attempting to make efforts that are achievable and make sense for the state and its residents.

MMAC update – Julie Smith, RN
• MMAC has been looking at details related to mid-level prescribers and found there to be some bad practices in place, such as using the wrong prescription pads, submitting with inconsistent signatures, etc. Complete findings will be submitted to the Bureau of Narcotics and Dangerous Drugs before moving forward. MHD will partner with MMAC to provide education.

Next Meeting:
Wednesday, November 20, 2019
1:00 PM to 4:00 PM
221 Metro Drive,
Jefferson City, MO